Back to search

Peptide record

TPDB05581

Antibacterial Antifungal Toxicity standard
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05581
Antibacterial Antifungal Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 8-aa standard natural multi-activity (Antibacterial, Antifungal, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
WWWLRRRW
Physicochemical Analysis
C68H89N21O9
ANDCEQGHIKMFPSTYV
W
1344.59
12.70
3
0
5
+3
-5.53
-1.663
48.75
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
22000
1636.19
0
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
0
K
0
M
0
F
0
P
0
S
0
T
4
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 4 Y: 0 V: 0
Chemical Descriptors
8
C68H89N21O9
1344.59
12.70
+3
-5.53
-1.663
Evidence Records 13 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2-8 µM

Target

Staphylococcus aureus USA300 LAC MRSA and 30 clinical strains

Source & Reference

NA

Other

Active against E. faecium V286-17 (anti-VRE) (MIC 2 uM), S. aureus USA300 LAC MRSA and 30 clinical strains (MIC 2-8 uM), K-pneumoniae E406-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17
Evidence 2 Activity

Activity

MIC
Antibacterial
32 µM

Target

A. baumannii B28-16

Source & Reference

NA

Other

USA300 LAC MRSA and 30 clinical strains (MIC 2-8 uM), K-pneumoniae E406-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17 (MIC >32 uM), and E. coli E423-17 (MIC 16-32 uM). It is primarily a
Evidence 3 Activity

Activity

MIC
Antibacterial
16-32 µM

Target

Escherichia coli E423-17

Source & Reference

NA

Other

-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17 (MIC >32 uM), and E. coli E423-17 (MIC 16-32 uM). It is primarily active against Gram+ pathogens, inlcuding 32 S. aureus clinical strains
Evidence 4 Activity

Activity

MIC50
Antibacterial
4 µM

Target

Staphylococcus aureus clinical strains

Source & Reference

NA

Other

coli E423-17 (MIC 16-32 uM). It is primarily active against Gram+ pathogens, inlcuding 32 S. aureus clinical strains (MIC50 4 uM). It killed most of MRSA in the 48 h preformed biofilms at 2-4 MIC.
Evidence 5 Activity

Activity

MIC
Antifungal
2-8 µM

Target

Staphylococcus aureus USA300 LAC MRSA and 30 clinical strains

Source & Reference

NA

Other

Active against E. faecium V286-17 (anti-VRE) (MIC 2 uM), S. aureus USA300 LAC MRSA and 30 clinical strains (MIC 2-8 uM), K-pneumoniae E406-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17
Evidence 6 Activity

Activity

MIC
Antifungal
32 µM

Target

A. baumannii B28-16

Source & Reference

NA

Other

USA300 LAC MRSA and 30 clinical strains (MIC 2-8 uM), K-pneumoniae E406-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17 (MIC >32 uM), and E. coli E423-17 (MIC 16-32 uM). It is primarily a
Evidence 7 Activity

Activity

MIC
Antifungal
16-32 µM

Target

Escherichia coli E423-17

Source & Reference

NA

Other

-17 (MIC >32 uM), A. baumannii B28-16 (MIC 32 uM), P-aeruginosa E411-17 (MIC >32 uM), and E. coli E423-17 (MIC 16-32 uM). It is primarily active against Gram+ pathogens, inlcuding 32 S. aureus clinical strains
Evidence 8 Activity

Activity

MIC50
Antifungal
4 µM

Target

Staphylococcus aureus clinical strains

Source & Reference

NA

Other

coli E423-17 (MIC 16-32 uM). It is primarily active against Gram+ pathogens, inlcuding 32 S. aureus clinical strains (MIC50 4 uM). It killed most of MRSA in the 48 h preformed biofilms at 2-4 MIC.
Evidence 9 Activity

Activity

50% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
50% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 10 Activity

Activity

LD50
Toxicity
>100 µM
Cytotoxic
LD50 | >100 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Two distinct amphipathic peptide antibiotics with systemic efficacy. | Proc Natl Acad Sci U S A | 2020
Evidence 11 Activity

Activity

LD50
Toxicity
>80 µM
Cytotoxic
LD50 | >80 | µM | target cell: Human hepatocyte cells HepaRG

Target

Human hepatocyte cells HepaRG

Source & Reference

NA
DBAASP
Two distinct amphipathic peptide antibiotics with systemic efficacy. | Proc Natl Acad Sci U S A | 2020
Evidence 12 Activity

Activity

LD50
Toxicity
>35 µM
Cytotoxic
LD50 | >35 | µM | target cell: Human lung fibroblasts MRC-9

Target

Human lung fibroblasts MRC-9

Source & Reference

NA
DBAASP
Two distinct amphipathic peptide antibiotics with systemic efficacy. | Proc Natl Acad Sci U S A | 2020
Evidence 13 Activity

Activity

LD50
Toxicity
>50 µM
Cytotoxic
LD50 | >50 | µM | target cell: Mouse splenocytes

Target

Mouse splenocytes

Source & Reference

NA
DBAASP
Two distinct amphipathic peptide antibiotics with systemic efficacy. | Proc Natl Acad Sci U S A | 2020